Compare
Harmony Biosciences Holdings, Inc. vs Ionis Pharmaceuticals Inc vs Madrigal Pharmaceuticals, Inc. vs Collegium Pharmaceutical, Inc
| Latest fiscal year | Harmony Biosciences Holdings, Inc. HRMY | Ionis Pharmaceuticals Inc IONS | Madrigal Pharmaceuticals, Inc. MDGL | Collegium Pharmaceutical, Inc COLL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $868.45M | $943.71M | $958.40M | $780.57M |
| Revenue growth (YoY) | +21.5% | +33.8% | +432.1% | +23.6% |
| Gross margin | 77.2% | n/a | n/a | 59.3% |
| Operating margin | 24.0% | -40.4% | -31.3% | 23.0% |
| Net margin | 18.3% | -40.4% | -30.1% | 8.1% |
| Net income | $158.69M | -$381.39M | -$288.28M | $62.87M |
| EPS (Diluted) | $2.71 | -$2.38 | -$12.85 | $1.73 |
| Operating cash flow | $348.20M | -$268.58M | -$189.55M | $329.32M |
| Free cash flow | $347.89M | -$320.03M | -$190.02M | $327.58M |
| Cash & equivalents | $752.50M | $372.26M | $198.69M | $231.25M |
| Total assets | $1.27B | $3.52B | $1.26B | $1.66B |
| Total liabilities | $401.41M | $3.03B | $656.90M | $1.36B |
| Shareholders' equity | $870.22M | $489.09M | $602.69M | $301.68M |
| Return on year-end equity | 18.2% | -78.0% | -47.8% | 20.8% |
| Shares outstanding | 57.73M | 163.30M | 22.84M | 31.71M |
Revenue, most recent five fiscal years
| Fiscal year | Harmony Biosciences Holdings, Inc. | Ionis Pharmaceuticals Inc | Madrigal Pharmaceuticals, Inc. | Collegium Pharmaceutical, Inc |
|---|---|---|---|---|
| Latest | $868.45M Ended 2025-12-31 | $943.71M Ended 2025-12-31 | $958.40M Ended 2025-12-31 | $780.57M Ended 2025-12-31 |
| 1 year earlier | $714.73M Ended 2024-12-31 | $705.14M Ended 2024-12-31 | $180.13M Ended 2024-12-31 | $631.45M Ended 2024-12-31 |
| 2 years earlier | $582.02M Ended 2023-12-31 | $787.65M Ended 2023-12-31 | $0 Ended 2023-12-31 | $566.77M Ended 2023-12-31 |
| 3 years earlier | $437.86M Ended 2022-12-31 | $587.37M Ended 2022-12-31 | $0 Ended 2022-12-31 | $463.93M Ended 2022-12-31 |
| 4 years earlier | $305.44M Ended 2021-12-31 | $810.46M Ended 2021-12-31 | $0 Ended 2021-12-31 | $276.87M Ended 2021-12-31 |